[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363391-105":59,"doc-detail-363391-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-the-study-of-pyrotinib-for-the-treatment-of-her2-positive-breast-cancer","Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer","","HER2-positive breast cancer is driven by aggressive tumor biology and intrinsic resistance to conventional treatments, creating a need for new targeted options. Pyrotinib is an irreversible pan-HER tyrosine kinase inhibitor that covalently binds HER1 (EGFR), HER2, and HER4, blocking downstream signaling and promoting tumor cell apoptosis. Clinical evidence supports efficacy across early and advanced settings. Its ability to cross the blood-brain barrier suggests benefit in patients with brain metastases, and this review summarizes pharmacology and recent clinical trials of pyrotinib-based regimens.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-the-study-of-pyrotinib-for-the-treatment-of-her2-positive-breast-cancer/363391/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-the-study-of-pyrotinib-for-the-treatment-of-her2-positive-breast-cancer/363391.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What mechanism of action does pyrotinib have in HER2-positive breast cancer?","Question",{"text":112,"@type":113},"Pyrotinib is an irreversible pan-HER tyrosine kinase inhibitor that covalently binds HER1 (EGFR), HER2, and HER4, suppressing downstream signaling and inhibiting tumor cell proliferation while inducing apoptosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is crossing the blood-brain barrier important for HER2-positive breast cancer treatment?",{"text":117,"@type":113},"The blood-brain barrier restricts penetration and distribution of many therapies within the CNS. Since many patients with metastatic HER2-positive disease develop brain metastases, BBB penetration offers a potential therapeutic advantage.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical development is highlighted for pyrotinib?",{"text":121,"@type":113},"The review summarizes recent clinical trials and therapeutic opportunities, emphasizing safety characteristics and efficacy of pyrotinib-based regimens across early-stage and advanced HER2-positive breast cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363391,1790221415,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Li et al. Breast Cancer Research (2026) 28:88 [https://doi.org/10.1186/s13058-026-02255-2](https://doi.org/10.1186/s13058-026-02255-2)  \nBreast Cancer Research  \nREVIEW Open Access  \nAdvances in the study of pyrotinib for the treatment of HER2-positive breast cancer  \nYan Li1,2, Wen Wang3, Yan Liang1,2, Houyun Lai1,2, Kun Mi2, Purong Zhang2, Jianhui Zhang2 andYixin Wang2*  \nAbstract  \nHER2-positive breast cancer is characterized by aggressive tumor biology and intrinsic resistance to conventional therapies, underscoring the need for novel targeted treatment approaches. Pyrotinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), covalently binds to the intracellular kinase domains of HER1 (EGFR), HER2, and HER4, thereby inhibiting downstream signaling pathways and inducing tumor cell apoptosis. Clinical investigations have consistently demonstrated the substantial therapeutic efficacy of pyrotinib in both early-stage and advanced HER2-positive breast cancer. Moreover, its ability to traverse the blood-brain barrier confers potential therapeutic advantages in patients with brain metastases. This comprehensive review provides a systematic overview of the pharmacological profile and mechanism of action of pyrotinib, with emphasis on recent clinical trials assessing pyrotinib-based regimens in HER2-positive breast cancer.  \nKeywords Pyrotinib, HER2-positive breast cancer, Tyrosine-kinase inhibitor (TKI), Targeted drug  \nIntroduction  \nBreast cancer remains one of the most prevalent malignancies among women globally, with persistently high incidence and mortality rates representing a major burden on public health systems [1–3]. Based on molecular biomarkers including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), breast cancer is classified into three major subtypes: hormone receptor (HR)-positive/HER2-negative (approximately 70%), HER2-positive (15–20%), and triple-negative (lacking all three standard molecular markers, around 15%) [4]. Among these subtypes,  \n*Correspondence: Yixin Wang [wyxlxn5@163.com](wyxlxn5@163.com)  \n1School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, China  \n2Affiliated Tumor Hospital of University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institute, Sichuan Cancer Prevention and Treatment Center, Chengdu 610041, Sichuan, China 3Suining Central Hospital, Suining 629000, Sichuan, China  \nHER2-positive breast cancer poses a significant clinical challenge due to its aggressive tumor biology, high risk of recurrence and distant metastasis, and poor overall prognosis5,6. Notably, up to 50% of patients with metastatic disease develop brain metastases, a complication associated with rising annual incidence [5, 6]. Notably, up to 50% of individuals diagnosed with HER2-positive metastatic breast cancer eventually develop brain metastases, with the reported annual incidence showing a rising trend [7]. The integrity of the blood-brain barrier (BBB) substantially restricts the effective penetration and distribution of many therapeutic agents, thus constituting a significant impediment to targeted drug delivery within the central nervous system (CNS) [8]. This poses a considerable challenge for large-molecule therapeutics such as monoclonal antibodies, exemplified by trastuzumaband pertuzumab [7, 9]. Therefore, the development of small-molecule tyrosine kinase inhibitor (TKI) capable of effectively cross the BBB has emerged as a crucial area of investigation in the management of HER2-positive breast cancer, especially in those with brain metastases [7, 10].  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) an","cbCaitNO31jNIWLC","https://ap.wps.com/l/cbCaitNO31jNIWLC","pdf",1659357,15,"English","# Abstract\n# Introduction\n## Breast cancer subtypes and clinical burden\n## Clinical challenges in HER2-positive disease\n## Rationale for BBB-penetrant HER TKI therapy\n# Pyrotinib background and pharmacology\n## Regulatory approval and mechanism of action\n## Pharmacokinetic profile and clinical development","[{\"question\":\"What mechanism of action does pyrotinib have in HER2-positive breast cancer?\",\"answer\":\"Pyrotinib is an irreversible pan-HER tyrosine kinase inhibitor that covalently binds HER1 (EGFR), HER2, and HER4, suppressing downstream signaling and inhibiting tumor cell proliferation while inducing apoptosis.\"},{\"question\":\"Why is crossing the blood-brain barrier important for HER2-positive breast cancer treatment?\",\"answer\":\"The blood-brain barrier restricts penetration and distribution of many therapies within the CNS. Since many patients with metastatic HER2-positive disease develop brain metastases, BBB penetration offers a potential therapeutic advantage.\"},{\"question\":\"What clinical development is highlighted for pyrotinib?\",\"answer\":\"The review summarizes recent clinical trials and therapeutic opportunities, emphasizing safety characteristics and efficacy of pyrotinib-based regimens across early-stage and advanced HER2-positive breast cancer.\"}]","Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer | PDF",1790151038,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ed41c86951f6cddc2a8d7c9c5ceb1f3.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/baa961d83ccb4a51fc24d402e0fe8833.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36847e44dc5cfae9ef7d2f45465f8a4a.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5401b742965065b8c90c0ecffc92a56e.webp",980,1306]